Notice: This company has been marked as potentially delisted and may not be actively trading. Alterity Therapeutics (PRAN) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesTrends PRAN vs. LUMO, RAPT, NXTC, CARM, LEXX, CLNN, LTRN, ACST, PMN, and IRDShould you be buying Alterity Therapeutics stock or one of its competitors? The main competitors of Alterity Therapeutics include Lumos Pharma (LUMO), RAPT Therapeutics (RAPT), NextCure (NXTC), Carisma Therapeutics (CARM), Lexaria Bioscience (LEXX), Clene (CLNN), Lantern Pharma (LTRN), Acasti Pharma (ACST), ProMIS Neurosciences (PMN), and Opus Genetics (IRD). These companies are all part of the "medical" sector. Alterity Therapeutics vs. Lumos Pharma RAPT Therapeutics NextCure Carisma Therapeutics Lexaria Bioscience Clene Lantern Pharma Acasti Pharma ProMIS Neurosciences Opus Genetics Lumos Pharma (NASDAQ:LUMO) and Alterity Therapeutics (NASDAQ:PRAN) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings, community ranking, media sentiment and profitability. Which has higher earnings & valuation, LUMO or PRAN? Alterity Therapeutics has lower revenue, but higher earnings than Lumos Pharma. Alterity Therapeutics is trading at a lower price-to-earnings ratio than Lumos Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLumos Pharma$2.05M18.27-$34.03M-$4.29-1.01Alterity Therapeutics$150K63.49-$6.40M-$0.70-1.53 Which has more risk & volatility, LUMO or PRAN? Lumos Pharma has a beta of 0.76, indicating that its share price is 24% less volatile than the S&P 500. Comparatively, Alterity Therapeutics has a beta of 1.05, indicating that its share price is 5% more volatile than the S&P 500. Do insiders and institutionals have more ownership in LUMO or PRAN? 34.0% of Lumos Pharma shares are held by institutional investors. Comparatively, 3.6% of Alterity Therapeutics shares are held by institutional investors. 25.4% of Lumos Pharma shares are held by company insiders. Comparatively, 38.8% of Alterity Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Do analysts recommend LUMO or PRAN? Lumos Pharma presently has a consensus target price of $8.63, indicating a potential upside of 99.19%. Given Lumos Pharma's stronger consensus rating and higher probable upside, analysts clearly believe Lumos Pharma is more favorable than Alterity Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lumos Pharma 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.00Alterity Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media prefer LUMO or PRAN? In the previous week, Alterity Therapeutics had 2 more articles in the media than Lumos Pharma. MarketBeat recorded 2 mentions for Alterity Therapeutics and 0 mentions for Lumos Pharma. Lumos Pharma's average media sentiment score of 0.00 equaled Alterity Therapeutics'average media sentiment score. Company Overall Sentiment Lumos Pharma Neutral Alterity Therapeutics Neutral Is LUMO or PRAN more profitable? Alterity Therapeutics has a net margin of 0.00% compared to Lumos Pharma's net margin of -1,583.49%. Alterity Therapeutics' return on equity of 0.00% beat Lumos Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Lumos Pharma-1,583.49% -233.03% -129.88% Alterity Therapeutics N/A N/A N/A Does the MarketBeat Community favor LUMO or PRAN? Alterity Therapeutics received 151 more outperform votes than Lumos Pharma when rated by MarketBeat users. However, 75.51% of users gave Lumos Pharma an outperform vote while only 57.67% of users gave Alterity Therapeutics an outperform vote. CompanyUnderperformOutperformLumos PharmaOutperform Votes3775.51% Underperform Votes1224.49% Alterity TherapeuticsOutperform Votes18857.67% Underperform Votes13842.33% SummaryAlterity Therapeutics beats Lumos Pharma on 10 of the 18 factors compared between the two stocks. Ad Darwin2025 AI Stock Picks: 2 Hidden Gems Under $10/ShareThe AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.👉[Click here to get your FREE report delivered instantly!] Get Alterity Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PRAN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRAN vs. The Competition Export to ExcelMetricAlterity TherapeuticsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.52M$6.52B$5.11B$8.84BDividend YieldN/A8.11%5.05%4.07%P/E Ratio-1.537.36108.8915.88Price / Sales63.49366.511,233.2287.15Price / CashN/A52.5939.9336.27Price / Book0.7610.176.946.36Net Income-$6.40M$153.36M$119.18M$226.00M Alterity Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRANAlterity TherapeuticsN/A$1.07+1.9%N/AN/A$9.52M$150,000.00-1.5314Gap UpLUMOLumos Pharma3.2304 of 5 stars$4.33+0.2%$8.63+99.2%+41.2%$37.45M$2.05M0.0030High Trading VolumeRAPTRAPT Therapeutics4.6044 of 5 stars$1.04-3.7%$9.50+817.9%-92.3%$36.18M$1.53M0.0080NXTCNextCure4.4003 of 5 stars$1.29-0.8%$4.00+210.1%+4.8%$36.13MN/A-0.6290CARMCarisma Therapeutics3.344 of 5 stars$0.85-1.2%$7.00+725.7%-64.7%$35.40M$14.92M-0.5420Gap UpLEXXLexaria Bioscience1.5258 of 5 stars$2.16-1.8%$11.00+409.3%+78.9%$34.17M$230,000.00-4.917News CoverageCLNNClene3.1977 of 5 stars$4.01-2.0%$71.33+1,678.9%-56.6%$33.52M$650,000.00-0.76100Analyst RevisionLTRNLantern Pharma1.0538 of 5 stars$2.95+0.3%N/A-27.0%$31.80MN/A0.0020ACSTAcasti Pharma2.366 of 5 stars$3.37-0.9%$10.00+196.7%+59.0%$31.68MN/A-2.3432PMNProMIS Neurosciences1.1238 of 5 stars$0.96-4.0%N/A-30.8%$31.22M$10,000.00-9.556IRDOpus Genetics2.7704 of 5 stars$0.98flat$8.00+712.9%N/A$31.07M$19.05M0.00N/ANews Coverage Related Companies and Tools Related Companies Lumos Pharma Competitors RAPT Therapeutics Competitors NextCure Competitors Carisma Therapeutics Competitors Lexaria Bioscience Competitors Clene Competitors Lantern Pharma Competitors Acasti Pharma Competitors ProMIS Neurosciences Competitors Opus Genetics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PRAN) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alterity Therapeutics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Alterity Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
